In a phase I/II trial conducted at a single institution involving patients diagnosed with recurrent, castration-sensitive prostate cancer, the researchers observed a significant reduction in PSA levels in 16 out of 21 patients (76%; p < 0.001) at the 20-week interval subsequent to the initial administration of GVAX treatment [34]. The gene discussed is KLK3; the disease is prostate cancer.